Home › Our Research › Psychopharmacology › Psychopharmacology: current projects › Depression

Depression

International study to predict optimised treatment - in depression (iSpotD)

Aim
An international phase IV effectiveness trial to identify genetic, neurophysiological and cognitive markers that predict specific response to the three most widely prescribed anti-depressant medications (Lexapro, Zoloft and Effexor) in major depression.
 
Participants
This study is currently recruiting participants who have depression.
 
Methods
People with depression will be randomly allocated to receive one of three approved and effective treatments: escitalopram, sertraline or venlafaxine.
 
Participants are involved in the study for approximately 1 year (52 weeks). There are two clinic visits (at baseline and week 8) during which genetic, cognitive and electrical brain function assessments will be conducted. Further, participants are contacted via phone for check ups.
 
Primary Researcher
Ms. Niharika Anand
 
 

Depression Outreach Study

Aim
The Depression Outreach Study is evaluating an investigational drug that is intended to be taken with your current antidepressant (SSRI), to see if it helps lesson any ongoing symptoms of depression.

Participants
This study is currently recruiting participants who have depression and are taking an SSRI medication, but still have some ongoing residual symptoms (like for example, tiredness, sadness or lack of interest).

Methods
This study will involve participants taking either the investigational drug or a placebo tablet once per day for ten weeks. Participants will visit our clinic each week for a check up during this time.

Participants are reimbursed between $30 - $40 for each visit to the clinic, and receive all medication free of charge.

Primary Researcher
Mr. Scott Santinon

 

 MAPrc Monash Alfred Psychiatry Research Centre, Level 1, Old Baker Building, Alfred Hospital, Melbourne 3008

 © MAPrc 2010. Designed and hosted by Infoxchange Australia